Cellectar Biosciences's total assets for Q3 2024 were $37.29M, an increase of 26.91% from the previous quarter. CLRB total liabilities were $20.75M for the fiscal quarter, a 32.80% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.